Sugi Predict

Sugi Predict / Compounds / SCHEMBL7656765

SCHEMBL7656765

SCHEMBL7656765

O=Cc1ccccc1OCCCCCCOc1ccccc1C=O

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.83
▸ HPGD P15428 1/20 0.83
▸ HTT P42858 1/20 0.83
▸ SMN1; SMN2 Q16637 1/20 0.83
▸ PTGDR2 Q9Y5Y4 1/20 0.61
▸ MAPT P10636 1/20 0.54
▸ KMT2A Q03164 5/20 0.54
▸ MEN1 O00255 3/20 0.54
▸ RAD52 P43351 1/20 0.54
▸ LMNA P02545 3/20 0.53
▸ GAA P10253 1/20 0.53
▸ TDP1 Q9NUW8 2/20 0.50
▸ SRC P12931 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ POLB P06746 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ PTK2B Q14289 1/20 0.48
▸ KDM4E B2RXH2 1/20 0.47
▸ RECQL P46063 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13305834 1.00 ALDH1A1 (0.83) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL21828406 1.00 ALDH1A1 (0.83) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8372730 0.98 ALDH1A1 (0.87) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL5805320 0.93 ALDH1A1 (0.87) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL7378757 0.92 ALDH1A1 (0.71) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL28847201 0.92 ALDH1A1 (0.71) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL7928970 0.92 ALDH1A1 (0.77) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL6914412 0.91 ALDH1A1 (1.00) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL3432906 0.91 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL1509382 0.91 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3487931-B1 HIGH-STRENGTH RUBBER COMPOSITION MICHELIN & CIE (FR) 2022-04-20 — — EP disclosed
US-10647848-B2 Rubber composition with a high level of fluidity based on an aromatic aldehyde and an aromatic polyphenol COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2020-05-12 — — US disclosed
EP-3390536-B1 RUBBER COMPOSITION WITH A HIGH LEVEL OF FLUIDITY BASED ON AN AROMATIC ALDEHYDE AND AN AROMATIC POLYPHENOL MICHELIN & CIE (FR) 2019-10-16 — — EP disclosed
WO-2018015668-A1 HIGH-STRENGTH RUBBER COMPOSITION COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2018-01-25 — — WO disclosed
WO-2017103404-A1 RUBBER COMPOSITION WITH A HIGH LEVEL OF FLUIDITY BASED ON AN AROMATIC ALDEHYDE AND AN AROMATIC POLYPHENOL COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN (FR) 2017-06-22 — — WO disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 — — US disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 — — US disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 — — US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 — — US disclosed
US-7211695-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-01 — — US disclosed
US-7211695-B2 β2-adrenergic receptor agonists THERAVANCE, INC. (US) 2007-05-01 — — US disclosed
US-7179794-B2 Multivalent macrolide antibiotics THERAVANCE, INC. (US) 2007-02-20 — — US disclosed
US-7179794-B2 Multivalent macrolide antibiotics THERAVANCE, INC. (US) 2007-02-20 — — US disclosed
US-7173039-B2 Protein kinase inhibitors THERAVANCE, INC. (US) 2007-02-06 — — US disclosed
US-7173039-B2 Protein kinase inhibitors THERAVANCE, INC. (US) 2007-02-06 — — US disclosed
US-6479498-B1 COMPRISE 2-10 SODIUM CHANNEL LIGANDS COVALENTLY CONNECTED BY A LINKER OR LINKERS THERAVANCE, INC. 2002-11-12 — — US disclosed
US-6420354-B1 Sodium channel drugs and uses ADVANCED MEDICINE, INC. 2002-07-16 — — US disclosed
US-5807974-A POLYARYLENEVINYLENE RESIN KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 1998-09-15 — — US disclosed
US-4120789-A REACTION WITH A BIS- OR TRIS-GUANYLHYDRAZONIUM SALT, DECANTING ANIC, S.P.A. (IT) 1978-10-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306134-A1 Muscarinic receptor antagonists CHRM3, CHRM5, CHRM2 ALDH1A1 2335/4885HPGD 1575/4885HTT 4424/4885
US-10647848-B2 Rubber composition with a high level of fluidity based on an aromatic aldehyde and an aromatic polyphenol AHR, POP1, RER1 ALDH1A1 85/4885HPGD 1274/4885HTT 2117/4885
US-20090111737-A1 Novel antibacterial agents ENGASE, PGLS, PEPD ALDH1A1 2244/4885HPGD 1223/4885HTT 4560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.